Ryuji Ohue-Kitano

Prof. Ryuji Ohue-Kitano


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
YYYuka Yamanouchi
Yuka Yamanouchi
SCSeita Chudan
Seita Chudan
RIRiko Ishibashi
Riko Ishibashi
RORyuji Ohue-Kitano
Ryuji Ohue-Kitano
MNMiyu Nishikawa
Miyu Nishikawa
YFYukihiro Furusawa
Yukihiro Furusawa

17 October 2024 in FASEB BioAdvances
Verified
Journal Article
Open access
ANAkari Nishida
Akari Nishida
RORyuji Ohue-Kitano
Ryuji Ohue-Kitano
YMYuki Masujima
Yuki Masujima
HNHazuki Nonaka
Hazuki Nonaka
MIMiki Igarashi
Miki Igarashi
IKIkuo Kimura
Ikuo Kimura
Overconsumption of food, especially dietary fat, leads to metabolic disorders such as obesity and type 2 diabetes. Long‐chain fatty acids, such as palmitoleate are recognized as the risk factors for these disorders owing to their high‐energy content and lipotoxicity. In contrast, medium‐chain fatty acids (MCFAs) metabolic benefits; however, their underlying molecular mechanisms remain unclear. GPR84 is an MCFA receptor, particularly for C10:0. Although evidence from in vitro experiments and oral administration of C10:0 in mice suggests that GPR84 is related to the metabolic benefits of MCFAs via glucose metabolism, its precise roles in vivo remain unclear. Therefore, the present study investigated whether GPR84 affects glucose metabolism and metabolic function using Gpr84 ‐deficient mice. Although Gpr84 ‐deficient mice were lean and had increased endogenous MCFAs under high‐fat diet feeding conditions, they exhibited hyperglycemia and hyperlipidemia along with lower plasma insulin and glucagon‐like peptide‐1 (GLP‐1) levels compared with wild‐type mice. Medium‐chain triglyceride (C10:0) intake suppressed obesity, and improved plasma glucose and lipid levels, and increased plasma GLP‐1 levels in wild‐type mice; however, these effects were partially attenuated in Gpr84 ‐deficient mice. Our results indicate that long‐term MCFA‐mediated GPR84 activation improves the dysfunction of glucose and lipid homeostasis. Our findings may be instrumental for future studies on drug development with GPR84 as a potential target, thereby offering new avenues for the treatment of metabolic disorders like obesity and type 2 diabetes.

11 July 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
MYMayu Yamano
Mayu Yamano
YYYuto Yamanaka
Yuto Yamanaka
SNShota Nishikawa
Shota Nishikawa
YMYuki Masujima
Yuki Masujima
RORyuji Ohue-Kitano
Ryuji Ohue-Kitano
IKIkuo Kimura
Ikuo Kimura
Background: GPR30 is a membrane-associated receptor involved in rapid, non-genomic estrogen signaling. Estrogen significantly influences hair growth and susceptibility to hair loss, with differences primarily driven by hormonal factors. While estrogen’s role in regulating hair follicle cycling is recognized, its precise molecular mechanisms remain unclear. This study investigates the role of GPR30 in hair follicle biology and evaluates its potential as a therapeutic target for estrogen-mediated hair loss disorders.Methods: The GPR30 selective agonist G-1 was administrated to female Gpr30-deficient mice with a C57BL/6J background and human hair follicle dermal papilla cell, and the effects on hair growth and the molecular signaling were evaluated.Results: We demonstrate that GPR30 is abundantly expressed in mouse skin, particularly during the anagen phase of the hair follicle cycle, implicating it in hair growth regulation. Activation of GPR30 using the selective agonist G-1 in mouse skin and human dermal papilla cells significantly upregulated Wnt/Hedgehog signaling, which are key pathways promoting hair growth. These effects were absent in Gpr30-deficient mice or in those administered a GPR30 antagonist, confirming the essential role of GPR30 in estrogen-mediated regulation of hair follicle activity.Conclusion: Our findings underscore the importance of GPR30 in modulating hair growth and suggest that GPR30, along with its selective agonists, holds promise as a novel therapeutic target for treating hair loss disorders and other estrogen-responsive conditions.

1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
Verified
Journal Article
Open access
PDF file
WKWatanabe Keita
Watanabe Keita
RORyuji Ohue-Kitano
Ryuji Ohue-Kitano
IKIkuo Kimura
Ikuo Kimura
Progesterone is a sex steroid hormone synthesized by the ovary, and plays a pivotal role for reproductive functions such as ovulation and the maintenance of pregnancy. Although these effects of progesterone have been implicated in nuclear progesterone receptors (PRs)-mediated classical signaling pathway, key pathways involved in non-classical progesterone signaling has been provided by the identification of membrane progesterone receptors (mPRα, mPRβ, mPRγ, mPRδ, and mPRε). Interestingly, mPRs may have been related to progesterone-mediated unknown rapid non-genomic action that cannot be currently explained by their genomic action through PRs. However, the structure, intracellular signaling, and physiological functions of these progesterone receptors are still unclear. In this study, we confirmed that mPRε, among mPRs receptors, is specifically expressed in the white adipose tissue (WAT), liver, and kidney of adult male and female mice. Furthermore, progesterone- mPRε signaling may contribute to suppression of glucose uptake and impair glucose tolerance in WAT. These findings provide new insights of regarding the non-genomic action of progesterone in metabolic homeostasis and novel therapeutic targets and strategies for metabolic disorder such as obesity and type 2 diabetes mellitus.